Ayala Pharmaceuticals (NASDAQ:ADXS) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research note issued to investors on Tuesday. The brokerage issued a sell rating on the stock.

Ayala Pharmaceuticals Price Performance

Ayala Pharmaceuticals stock opened at $0.03 on Tuesday. The firm has a fifty day simple moving average of $0.05 and a two-hundred day simple moving average of $0.11. Ayala Pharmaceuticals has a twelve month low of $0.00 and a twelve month high of $1.49. The company has a market capitalization of $1.15 million, a PE ratio of 0.00 and a beta of 1.81.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.